News & Analysis on Clinical Trial Services & Contract Research And Development
Sweetch: $20m investment
By Jenni Spinner
- Last updated on
Digital therapeutics specialist Sweetch has landed $20m USD in Series A funding. The investment reportedly will be used to support development and adoption of its automated personalized engagement technology between patients with chronic conditions and health system staff.
“We believe that every person with chronic conditions should have a trusted voice empowering them to reach their micro-goals every step of the way throughout their unique health journey,” said Yoni Nevo, CEO of Sweetch. “The rapidly evolving remote health era is missing a critical component: effective continuous relationships between pharmaceutical companies, device manufacturers, payers, healthcare providers and each of their individual patients; Sweetch provides this missing critical capability at scale to outsmart chronic conditions, together.”